Skip to content
type1.science

MiniMed Flex pump

MiniMed

What it is

MiniMed's FDA-cleared, screenless, smartphone-controlled tubed pump: about half the size of the 780G, with app bolusing, a 300-unit reservoir, rechargeable battery lasting at least seven days, waterproofing, and compatibility with both Simplera Sync and the Abbott-built Instinct sensor. US commercial launch began on 17 June 2026.

Editorial review: .

Most recent recorded citation date: 2026-10-15. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

US — availableRegulator-approvedpumptubedphone-controlsmartguardminimedfda-clearedOfficial site ↗

Evidence behind this assessment

Key evidence notes. Study results, product eligibility and access answer different questions.

Who was studied?
Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
Benefit or performance
Reliability: FDA-cleared and built on MiniMed's mature pump/SmartGuard lineage, though the Flex hardware itself has a shorter post-market track record and a narrow 20-unit early-release factory-verification recall (Z-0088-2027).[2]
Important harms and treatment burden
Read the safety discussion and original sources. A missing summary does not establish safety.
Approval and country access
US commercial launch began June 2026; not yet available outside the USApproval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
Follow-up and remaining uncertainty
Read the full discussion and original sources for follow-up duration and study limitations.

This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.

Editorial score: calculation and evidence

A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.

Default calculation: 66 × 20 + 64 × 20 + 72 × 20 + 90 × 15 + 82 × 10 + 58 × 15 = 7080; divide by total weight 100. Unrounded weighted result: 70.8.

Interoperability66

US commercial shipping includes both the Simplera Sync sensor and the Abbott-built 15-day Instinct sensor (since 17 August 2026), running MiniMed's SmartGuard algorithm; remains a closed MiniMed ecosystem rather than an open ACE pump.[6]

Reliability64

FDA-cleared and built on MiniMed's mature pump/SmartGuard lineage, though the Flex hardware itself has a shorter post-market track record and a narrow 20-unit early-release factory-verification recall (Z-0088-2027).[2]

Form factor72

Small and screenless, about half the 780G form factor, though still a tubed pump rather than a patch pump.[2]

Phone control90

Designed around MiniMed app control on iOS and Android, including meal and correction boluses from a compatible smartphone.[1]

Capacity82

300-unit reservoir and a rechargeable battery lasting at least seven days are strong for a compact pump; it also works with MiniMed's Extended infusion set, worn up to seven days.[4]

Access & cost58

US commercial launch began on 17 June 2026 (type 1 diabetes from age 7, and adults 18+ with insulin-requiring type 2), Medicare and Medicare Advantage access began on 22 July 2026, and CE marking was announced on 1 September 2026 with European rollout targeted for November 2026.[5]

The full picture

MiniMed Flex is the hardware shift in MiniMed's next generation: a screenless tubed pump controlled through the MiniMed app. It preserves the 300-unit capacity and MiniMed infusion-set ecosystem while shrinking the pump and moving bolusing to the phone. Its ranking is deliberately split from the AID-system page: this pump score is about hardware access, form factor and interoperability; the AID page covers SmartGuard automation and the GATEWAY no-meal-bolus signal.

It is now actually shipping

Flex has moved from "cleared" to "on sale". MiniMed announced the start of its first US commercial launch on 17 June 2026, following FDA clearance in March 2026.4 It is indicated for type 1 diabetes from age 7, and for adults 18 and over with insulin-requiring type 2 diabetes. The pump launches with the Simplera Sync sensor, has no screen (control is entirely through the MiniMed app on iOS or Android from day one), holds 300 units, and works with MiniMed's infusion sets — including the Extended set, worn for up to seven days.4 That is why the access score moves up: this is a product you can be prescribed today rather than a clearance you are waiting on. It is still a US-only launch, and payer coverage is only starting to fall into place, which is what keeps the score in the middle of the range rather than near the top.

On 22 July 2026, MiniMed expanded US access to Medicare and Medicare Advantage beneficiaries.5 On 17 August 2026 MiniMed announced that Flex is commercially shipping in the US with Instinct, so customers can now order Flex with Instinct or Simplera Sync; existing Flex users need MiniMed app 1.3.1 plus a pump-software update to pair Instinct.6 Shipping is not Flex-specific outcome data. European CE marking was announced on 1 September 2026, with commercial launch targeted November 2026.8 On 15 October 2026, MiniMed completed its corporate separation from Medtronic as an independent public company (NASDAQ: MMED).10

Targeted early-release hardware recall (Z-0088-2027). On 5 October 2026, the FDA classified a Class II recall (Z-0088-2027, MiniMed Notice 33 issued 14 September 2026) covering 20 early-release field units (MMT-8062 / MMT-8072; 299 total units identified, with 279 quarantined before shipping) that did not complete all standard factory verification tests prior to release, creating a potential risk of unexpected pump errors or interrupted insulin delivery; no serious injuries or deaths had been reported, and MiniMed contacted the 20 affected users directly for overnight replacement.11

September regulatory update. Flex has received CE marking, with European launch targeted November 2026. US commercial availability does not imply that European sales have begun.8

What's next for this

  • →European launch following CE mark; company target, not current European availability · November 2026
  • →Vivera fully closed-loop algorithm, subject to regulatory review · US launch targeted second half of 2027

Sources

  1. [1]
  2. [2]
  3. [3]
  4. [4]
    MiniMed begins miniature Flex pump rollout in US · Science journalism · 2026-06-17

    Drug Delivery Business News. MiniMed begins miniature Flex pump rollout in US. Drug Delivery Business News (17 June 2026).

  5. [5]
    MiniMed Flex now available to Medicare and Medicare Advantage beneficiaries · Manufacturer · 2026-07-22 — Confirms current US Medicare access and says the launched Simplera Sync configuration will gain Abbott-made Instinct compatibility later in summer 2026.

    MiniMed. MiniMed Flex Now Available to Medicare and Medicare Advantage Beneficiaries (22 July 2026).

  6. [6]
    MiniMed's Smallest App-Controlled Insulin Pump Now Shipping with the World's Smallest Sensor · Manufacturer · 2026-08-17 — MiniMed Flex now commercially shipping in the US with Instinct (Abbott). Customers can order Flex with Instinct or Simplera Sync. Shipping is not the same as Flex-specific glycemic outcomes.

    MiniMed. MiniMed's Smallest App-Controlled Insulin Pump Now Shipping with the World's Smallest Sensor (17 August 2026).

  7. [7]
    Closed-loop updates from ADA 2026 (conference reporting) · Conference finding — Conference round-up, not a MiniMed statement — the European launch and Vivera software-update timelines below rest on this reporting alone.
  8. [8]
    MiniMed September 2026 pipeline and launch update · Manufacturer · 2026-09-01

    MiniMed. September 2026 pipeline and commercial update.

  9. [9]
    FDA Class II Recall Z-0088-2027 — MiniMed Flex Insulin Pump (MMT-8062 / MMT-8072) factory verification notice · Regulatory decision · 2026-10-05 — Covers 20 early-release field units (out of 299 total units, with 279 quarantined before shipping) that did not complete all standard factory verification tests; no serious injuries or deaths reported; overnight replacement provided (MiniMed Notice 33, 14 September 2026).
  10. [10]
    MiniMed Completes Separation from Medtronic as an Independent Public Company (NASDAQ: MMED) · Manufacturer · 2026-10-15

    MiniMed. MiniMed Completes Separation from Medtronic (15 October 2026).

  11. [11]

    U.S. FDA. Class II Device Recall MiniMed Flex Insulin Pump — Z-0088-2027 (classified 5 October 2026; MiniMed Notice 33 dated 14 September 2026; 20 field units MMT-8062 / MMT-8072 with incomplete factory verification tests; overnight replacement provided). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=222528 and https://www.minimed.com/en-us/safety-notices/notice33-letter